Fluid Pharma was honoured to present its pioneering anti-malarial therapy at the UK Parliament on Monday, 8 September, during the event “Innovation to Action: Harnessing UK Research for Global Health Solutions.”

The event formed part of a high-level South African parliamentary exchange visit, coordinated by STOPAIDS and WACI Health. It provided a platform to demonstrate how UK research and innovation are driving global health impact—showcasing how UK expertise, supported through partnerships with Unitaid and the UK Government, is transforming lives worldwide.

In 2023, malaria claimed 597,000 lives, the majority being young children. Fluid Pharma’s taste-masked Artesunate/Amodiaquine (ASAQ) micro-pellets represent the first child-friendly ASAQ formulation for treating malaria in African children. Developed using the company’s proprietary MicroCoat® technology and funded by Unitaid, the formulation delivers a palatable, easy-to-administer treatment without added sugar, flavouring agents, or the need for clean water—an essential advantage in low- and middle-income countries (LMICs).

This project underscores Fluid Pharma’s commitment to leveraging MicroCoat® technology to advance paediatric treatments and improve global health outcomes.